← All candidates
174 insider filings on record.
174 filings on record.
NBIXNEUROCRINE BIOSCIENCES INC
NasdaqGS · Healthcare · $15.25B
$150.02
174 insider filings on record.
None of them an open-market buy in the last year.
No price data yet — the yfinance scanner hasn't produced bars for NBIX.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$15.25B
Float
100.4M
99% public
Short % float
Pro
Price / profit
21.9
Price / future profit
12.5
Price / sales
4.5
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
169 more transactions on Pro →Context
Wall St
$197.95 avg target
+31.9% vs today · 27 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 4 quarters beat
Q1 '26$1.94 act+$0.24
Q4 '25$1.88 act−$0.42
Q3 '25$2.17 act+$0.10
Q2 '25$1.65 act+$0.15
Coverage
Reasons Why Investors Should Consider Betting on Neurocrine StockZacks · 07-06Zacks.com featured highlights include Neurocrine Biosciences, MYR Group, Block, Delek US Holdings and Dycom IndustriesZacks · 07-02Neurocrine (NBIX) Reports Clinically Meaningful Benefits in 94% of Patients Treated for Tardive DyskinesiaInsider Monkey · 07-01Neurocrine Biosciences (NBIX) Is Up 6.46% in One Week: What You Should KnowZacks · 07-01
The file stays open
174 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice